CFM Wealth Partners LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

CFM Wealth Partners LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 9.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,424 shares of the biopharmaceutical company’s stock after acquiring an additional 2,238 shares during the period. CFM Wealth Partners LLC’s holdings in Pfizer were worth $701,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $26,000. Gladius Capital Management LP grew its stake in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares in the last quarter. Quarry LP bought a new stake in Pfizer during the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America purchased a new position in Pfizer in the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management raised its position in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. UBS Group cut their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $26.51 on Monday. The stock has a market cap of $150.20 billion, a P/E ratio of 35.82, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The firm’s fifty day simple moving average is $26.27 and its 200 day simple moving average is $27.86. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.49%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.